|
07.11.2024 12:08:57
|
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024.
Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions.
ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.
Live audio webcast
The meeting will be audio webcasted live and be available for replay on ALK’s website https://ir.alk.net
Conference call
If you wish to participate via telephone, please register for the conference call by using this link: Registration - ALK 9M (Q3) 2024 - telephone conference and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register on the day before the call at the latest.
Presentation
The presentation slides will be available on https://ir.alk.net shortly before the meeting starts.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Nachrichten zu Alk-Abello A-S Bearer and-or registered Shs -B-
|
18.12.24 |
Positive results advance peanut tablet to phase II development (GlobeNewswire) | |
|
12.12.24 |
ACARIZAX® approved in Europe for treatment of young children (GlobeNewswire) | |
|
13.11.24 |
Ausblick: Alk-Abello A-S Bearer and-or registered B vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
09.11.24 |
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire) | |
|
30.10.24 |
Erste Schätzungen: Alk-Abello A-S Bearer and-or registered B mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
|
22.08.24 |
Ausblick: Alk-Abello A-S Bearer and-or registered B gewährt Anlegern Blick in die Bücher (finanzen.net) | |
|
08.08.24 |
Erste Schätzungen: Alk-Abello A-S Bearer and-or registered B vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Alk-Abello A-S Bearer and-or registered Shs -B-
3 Knaller-Aktien im BX Musterportfolio📈: Palo Alto Networks, Fiserv & Motorola Solutions
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Motorola Solutions
✅ Fiserv Inc.
✅ Palo Alto Networks
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Alk-Abello A-S Bearer and-or registered Shs -B- | 161.50 | 5.56% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
US-Zinsentscheid im Blick: Wall Street verabschiedet sich tiefrot -- SMI schliesst im Minus -- DAX beendet Handel stabil -- Asiens Börsen letztlich mehrheitlich in GrünDer heimische Aktienmarkt zeigte sich am Mittwoch verlustreich. Der deutsche Aktienmarkt tendierte unterdessen wenig bewegt. Die US-Börsen präsentierten sich am Mittwoch mit kräftigen Verlusten. Die asiatischen Börsen bewegten sich zur Wochenmitte mehrheitlich im Plus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |